1. |
Menconi F, Marcocci C, Marino M. Diagnosis and classification of Graves’ disease. Autoimmun Rev 2014; 4-5(13):398-402. doi: 10.1016/j.autrev.2014.01.013.
|
2. |
Bossowski A, Stasiak-Barmuta A, Urban M. Relationship between CTLA-4 and CD28 molecule expression on T lymphocytes and stimulating and blocking autoantibodies to the TSH-receptor in children with Graves’ disease. Horm Res 2005; 4(64):189-97. doi: 10.1159/000088875.
|
3. |
Garapati VP, Lefranc MP. IMGT Colliers de Perles and IgSF domain standardization for T cell costimulatory activatory (CD28, ICOS) and inhibitory (CTLA-4, PDCD1 and BTLA) receptors. Dev Comp Immunol 2007; 10(31):1050-72. doi: 10.1016/j.dci.2007.01.008.
|
4. |
Pawlak-Adamska E, Frydecka I, Bolanowski M, et al. CD28/CTLA-4/ICOS haplotypes confers susceptibility to Graves’ disease and modulates clinical phenotype of disease. Endocrine 2017; 1(55):186-99. doi: 10.1007/s12020-016-1096-1.
|
5. |
Watanabe N, Nakajima H. Coinhibitory molecules in autoimmune diseases. Clin Dev Immunol 2012; 2012:269756. doi: 10.1155/2012/269756.
pmid: 22997525
|
6. |
Turka LA, Ledbetter JA, Lee K, et al. CD28 is an inducible T cell surface antigen that transduces a proliferative signal in CD3+ mature thymocytes. J Immunol 1990; 5(144):1646-53.
|
7. |
Matsuoka N, Eguchi K, Kawakami A, et al. Lack of B7-1/BB1 and B7-2/B70 expression on thyrocytes of patients with Graves’ disease. Delivery of costimulatory signals from bystander professional antigen-presenting cells. J Clin Endocrinol Metab 1996; 11(81):4137-43. doi: 10.1210/jcem.81.11.8923872.
|
8. |
Eagar TN, Karandikar NJ, Bluestone JA, et al. The role of CTLA-4 in induction and maintenance of peripheral T cell tolerance. Eur J Immunol 2002; 4(32):972-81. doi: 10.1002/1521-4141(200204)32:4<972::AID-IMMU972>3.0.CO;2-M.
|
9. |
Hutloff A, Dittrich AM, Beier KC, et al. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature 1999; 6716(397):263-6. doi: 10.1038/16717.
|
10. |
Wassink L, Vieira PL, Smits HH, et al. ICOS expression by activated human Th cells is enhanced by IL-12 and IL-23: increased ICOS expression enhances the effector function of both Th1 and Th2 cells. J Immunol 2004; 3(173):1779-86. doi: 10.4049/jimmunol.173.3.1779.
|
11. |
Ishida Y, Agata Y, Shibahara K, et al. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 1992; 11(11):3887-95.
pmid: 1396582
|
12. |
Carter LL, Carreno BM. Cytotoxic T-lymphocyte antigen-4 and programmed death-1 function as negative regulators of lymphocyte activation. Immunol Res 2003; 1(28):49-59. doi: 10.1385/IR:28:1:49.
|
13. |
Watanabe N, Gavrieli M, Sedy JR, et al. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat Immunol 2003; 7(4):670-9. doi: 10.1038/ni944.
|
14. |
Sedy JR, Gavrieli M, Potter KG, et al. B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator. Nat Immunol 2005; 1(6):90-8. doi: 10.1038/ni1144.
|
15. |
Monney L, Sabatos CA, Gaglia JL, et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature 2002; 6871(415):536-41. doi: 10.1038/415536a.
|
16. |
Zhu C, Anderson AC, Schubart A, et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol 2005; 12(6):1245-52. doi: 10.1038/ni1271.
|
17. |
Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001; 4(104):487-501.
|
18. |
Hollenbaugh D, Grosmaire LS, Kullas CD, et al. The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co-stimulatory activity. EMBO J 1992; 12(11):4313-21.
|
19. |
Hassan GS, Merhi Y, Mourad WM. CD154 and its receptors in inflammatory vascular pathologies. Trends Immunol 2009; 4(30):165-72. doi: 10.1016/j.it.2009.01.004.
|
20. |
Watts TH. TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol 2005; 23:23-68. doi: 10.1146/annurev.immunol.23.021704.115839.
doi: 10.1146/annurev.immunol.23.021704.115839
pmid: 15771565
|
21. |
Gramaglia I, Jember A, Pippig SD, et al. The OX40 costimulatory receptor determines the development of CD4 memory by regulating primary clonal expansion. J Immunol 2000; 6(165):3043-50.
|
22. |
Lumachi F, Basso SM, Orlando R. Cytokines, thyroid diseases and thyroid cancer. Cytokine 2010; 3(50):229-33. doi: 10.1016/j.cyto.2010.03.005.
|
23. |
Ansar AS, Young PR, Penhale WJ. Beneficial effect of testosterone in the treatment of chronic autoimmune thyroiditis in rats. J Immunol 1986; 1(136):143-7.
|
24. |
Fassler R, Dietrich H, Kromer G, et al. The role of testosterone in spontaneous autoimmune thyroiditis of Obese strain (OS) chickens. J Autoimmun 1988; 1(1):97-108.
doi: 10.1016/0896-8411(88)90081-9
pmid: 3076054
|
25. |
Paschke R, Schuppert F, Taton M, et al. Intrathyroidal cytokine gene expression profiles in autoimmune thyroiditis. J Endocrinol 1994; 2(141):309-15.
|
26. |
Endo T, Kobayashi T. Immunization with thyroglobulin induces Graves’-like disease in mice. J Endocrinol 2009; 2(202):217-22. doi: 10.1677/JOE-09-0089.
|
27. |
Liu L, Wu L, Gao A, et al. The influence of dihydrotestosterone on the development of Graves’ disease in female BALB/c mice. Thyroid 2016; 3(26):449-57. doi: 10.1089/thy.2015.0620.
|
28. |
Chen CR, Pichurin P, Nagayama Y, et al. The thyrotropin receptor autoantigen in Graves disease is the culprit as well as the victim. J Clin Invest 2003; 12(111):1897-904. doi: 10.1172/JCI17069.
|
29. |
Nagayama Y, Mizuguchi H, Hayakawa T, et al. Prevention of autoantibody-mediated Graves’-like hyperthyroidism in mice with IL-4, a Th2 cytokine. J Immunol 2003; 7(170):3522-7.
|
30. |
Mostafa S, Seamon V, Azzarolo AM. Influence of sex hormones and genetic predisposition in Sjogren’s syndrome: a new clue to the immunopathogenesis of dry eye disease. Exp Eye Res 2012; 1(96):88-97. doi: 10.1016/j.exer.2011.12.016.
|
31. |
Wu L, Xun L, Yang J, et al. Induction of murine neonatal tolerance against Graves’ disease using recombinant adenovirus expressing the TSH receptor A-subunit. Endocrinology 2011; 3(152):1165-71. doi: 10.1210/en.2010-0737.
|
32. |
Yessoufou A, Ple A, Moutairou K, et al. Docosahexaenoic acid reduces suppressive and migratory functions of CD4+CD25+ regulatory T-cells. J Lipid Res 2009; 12(50):2377-88. doi: 10.1194/jlr.M900101-JLR200.
|
33. |
Han LF, Qiu WM, Hu C, et al. Therapeutic effects of B and T lymphocyte attenuator extracellular domain and heat shock protein 70 antigen peptide on cervical cancer in mouse model. Zhonghua Fu Chan Ke Za Zhi 2010; 8(45):603-8.
|
34. |
Bishop KD, Harris JE, Mordes JP, et al. Depletion of the programmed death-1 receptor completely reverses established clonal anergy in CD4(+) T lymphocytes via an interleukin-2-dependent mechanism. Cell Immunol 2009; 1-2(256):86-91. doi: 10.1016/j.cellimm.2009.01.008.
|
35. |
Lech M, Susanti HE, Rommele C, et al. Quantitative expression of C-type lectin receptors in humans and mice. Int J Mol Sci 2012; 8(13):10113-31. doi: 10.3390/ijms130810113.
|
36. |
Teague TK, Tan C, Marino JH, et al. CD28 expression redefines thymocyte development during the pre-T to DP transition. Int Immunol 2010; 5(22):387-97. doi: 10.1093/intimm/dxq020.
|
37. |
Zang YS, Fang Z, Liu YA, et al. Repressor of GATA-3 can negatively regulate the expression of T cell cytokines through modulation on inducible costimulator. Chin Med J (Engl) 2012; 12(125):2188-94.
|
38. |
Tone Y, Kojima Y, Furuuchi K, et al. OX40 gene expression is up-regulated by chromatin remodeling in its promoter region containing Sp1/Sp3, YY1, and NF-kappa B binding sites. J Immunol 2007; 3(179):1760-7.
|
39. |
Vavassori S, Shi Y, Chen CC, et al. In vivo post-transcriptional regulation of CD154 in mouse CD4+ T cells. Eur J Immunol 2009; 8(39):2224-32. doi: 10.1002/eji.200839163.
|
40. |
Frauwirth KA, Thompson CB. Activation and inhibition of lymphocytes by costimulation. J Clin Invest 2002; 3(109):295-9. doi: 10.1172/JCI14941.
|
41. |
Yoshie N, Watanabe M, Inoue N, et al. Association of polymorphisms in the ICOS and ICOSL genes with the pathogenesis of autoimmune thyroid diseases. Endocr J 2016; 1(63):61-8. doi: 10.1507/endocrj.EJ15-0435.
|
42. |
Wang H, Zhu LS, Cheng JW, et al. CD40 ligand induces expression of vascular cell adhesion molecule 1 and E-selectin in orbital fibroblasts from patients with Graves’ orbitopathy. Graefes Arch Clin Exp Ophthalmol 2015; 4(253):573-82. doi: 10.1007/s00417-014-2902-1.
|
43. |
Dong C, Nurieva RI, Prasad DV. Immune regulation by novel costimulatory molecules. Immunol Res 2003; 1(28):39-48. doi: 10.1385/IR:28:1:39.
|
44. |
Kaneyama T, Tomiki H, Tsugane S, et al. The TIM-3 pathway ameliorates Theiler’s murine encephalomyelitis virus-induced demyelinating disease. Int Immunol 2014; 7(26):369-81. doi: 10.1093/intimm/dxt056.
doi: 10.1093/intimm/7.3.369
|
45. |
Seki M, Oomizu S, Sakata KM, et al. Galectin-9 suppresses the generation of Th17, promotes the induction of regulatory T cells, and regulates experimental autoimmune arthritis. Clin Immunol 2008; 1(127):78-88. doi: 10.1016/j.clim.2008.01.006.
|
46. |
Fijak M, Schneider E, Klug J, et al. Testosterone replacement effectively inhibits the development of experimental autoimmune orchitis in rats: evidence for a direct role of testosterone on regulatory T cell expansion. J Immunol 2011; 9(186):5162-72. doi: 10.4049/jimmunol.1001958.
|